Stocks · News reference

YD Bio Announces Launch Of Two Chrono-Nutrition Supplement Formulations In Taiwan Developed With Chronic Disease Healthcare Association And Future Health Institute

Aug 11, 2026, 12:02 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 25, 2026, 12:03 PMBenzinga Newsdesk
YD Bio Publishes Review Article Titled Beyond Bone Health: Exploring The ‘Heart–Brain–Bone’ Axis Modulated By Lipid-Soluble Nutrients
YD Bio Limited ("YD Bio" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic innovations, today announced the
Read original at benzinga
YDES
BenzingaAug 17, 2026, 9:06 PMBenzinga Insights
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers INVO Fertility (NASDAQ:IVF) stock moved upwards by 13.1% to $1.73 during Monday's after-market session. The company's market cap stands at $1.7 million. The company's, Q2 earnings came out today.
Read original at benzinga
AMLX APUS DCGO GELS GNPX
Globenewswire IncJul 2, 2026, 12:00 PMYd Bio Limited
YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations
YD Bio announced that its affiliate EG BioMed US obtained out-of-state clinical laboratory licenses in Rhode Island and Pennsylvania, expanding its CLIA-certified laboratory's authorized operating footprint to 46 U.S. states plus Washington D.C. and Guam. The expansion supports the company's DNA methylation-based early cancer detection operations and broadens patient access to blood-based testing services for various cancers.
Read original at globenewswire-inc
YDES YDESW